$0.23
▲ +0.8% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
Overview
52-week range
$0.19
$2.89
1% of range
Avg surprise (last 2)
+45.1%
Avg reaction (last 1)
-3.8%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.43 | — | — | — | — | financials |
| Fri May 15, 2026 | Mar/2026 | $-0.69 | $-1.08 | +36.1% | — | -3.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $1.57 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-3.68 | $8.00 | +54.0% | — | — | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-0.05 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-6.00 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-3.00 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.12 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.16 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.10 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.08 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26,000 | $22,000 | — | $26,000 | $25,000 | $16,000 | — | $35,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-4M | $-2M | — | $-2M | $-3M | $-4M | — | $-4M |
| Net income | $-4M | $-3M | — | $-3M | $-3M | $-4M | — | $-4M |
| EPS (diluted) | $-0.43 | $-0.69 | — | $1.57 | $-3.68 | $-0.05 | — | $-6.00 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10M | $6M | $3M | $2M | $476,000 | $898,000 | $2M | $915,000 |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $10M | $6M | $3M | $3M | $1M | $3M | $4M | $8M |
| Total assets | $13M | $9M | $6M | $5M | $4M | $6M | $9M | $14M |
| Long-term debt | $4M | $210,000 | $927,000 | — | $3M | $2M | — | $139,000 |
| Total liabilities | $5M | $6M | $16M | $12M | $11M | $10M | $10M | $11M |
| Total equity | $8M | $2M | $-10M | $-6M | $-7M | $-4M | $-1M | $3M |
Implied volatility — last 90 days
No IV snapshots yet for AIM.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.